Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

DiaMedica DMAC DM199 phase 2 data; FGR enrollment; 2027 runway

Aug 10, 2026, 4:35 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive Phase 2 DM199 topline in preeclampsia, first FGR cohort enrollment, and regulatory progress (Canada) combine with a clear cash runway to support near-term upside, despite ongoing losses and development risk typical of clinical-stage biotechs.

AI summary

What happened, with direct paths to the underlying reporting

DiaMedica reports encouraging Phase 2 DM199 data in preeclampsia and completes enrollment for the first fetal growth restriction cohort, with a September KOL call planned. The AIS interim readout is slated for early 2027, while Health Canada has approved a Phase 2 PE study with first patient in Q4 2026, supported by a cash runway through 2027.

Enrollment of first FGR cohort completed; KOL call scheduled for September.
Phase 2 PE Part 1a topline: SBP down 29.1 mmHg, DBP down 17.0; SBP <160 for 24h.
AIS ReMEDy2 interim analysis expected early 2027; ~70 sites across US/Canada/UK/Europe.
$43.5M cash and investments as of 6/30/2026; runway through 2027.
Health Canada authorizes global Phase 2 PE study; first patient due in Q4 2026.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

DiaMedica DMAC DM199 phase 2 data; FGR enrollment; 2027 runway

DiaMedica to Report Q4 Earnings Amid Positive Phase 2 Study Clearance